Hyperfine, Inc. Reports Second Quarter 2026 Financial Results
Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
How this was made
The 30-second read
Why it matters
Traders can update models using the reported Q2 revenue, gross margin, system sales, and the stated FY2026 revenue and cash-burn guidance ranges, plus Europe regulatory and launch progress.
Market read
A primary-source earnings-and-guidance disclosure with concrete financial figures and full-year targets, plus Europe regulatory/launch milestones and clinical evidence highlights.
What to watch
Warrant-liability fair value drove part of the net loss; investors may adjust earnings quality and scrutinize cash burn assumptions behind the FY2026 guidance.
Background
This SEC 8-K (Item 2.02) summarizes Hyperfine’s Q2 2026 financial results and business updates for its FDA-cleared portable MR brain imaging system, Swoop.
Ticker impact
Hyperfine reported Q2 2026 revenue of $3.9M (+44.8% YoY), 12 system sales, and guided FY2026 revenue to $20M-$22M.
Likely positive bias if investors view gross margin expansion and guidance as validating broader Swoop adoption; downside risk if cash burn or operating expense trends worry the market.
The filing includes explicit Q2 financial results (revenue, gross margin, net loss) and management’s FY2026 guidance ranges, which are direct inputs to valuation and forward expectations.
Market effects
Reinforces the portable MRI adoption narrative and may influence sentiment toward early-stage medical imaging and AI-enabled diagnostic hardware/software names.
CE/UKCA progress and European launch details can improve regional commercial outlook for EU/UK healthcare procurement cycles.
International expansion milestones and PRIME study messaging may affect global investor perception of clinical evidence and scalability.
Counterpoint
Despite revenue growth, the company still reported a large net loss and higher SG&A, so the market may focus on path to profitability rather than top-line momentum.
Key entities
- issuerHyperfine, Inc.
Nasdaq-listed company reporting Q2 2026 results and FY2026 guidance for its Swoop portable MR imaging system.
- productSwoop system
FDA-cleared portable, ultra-low-field MR brain imaging system central to the company’s revenue and adoption narrative.
- productOptive AI software
AI software referenced in Europe regulatory approvals and commercialization updates.
